Summary
This pilot randomised controlled trial examined the efficacy of HMB-containing oral nutritional supplement in 21 patients with stable decompensated cirrhosis and sarcopenia over 12 weeks. Whilst the intervention did not significantly increase muscle mass or handgrip strength compared to control, it produced within-group improvements in phase angle, mid-arm muscle circumference, and chair stand test performance. The authors conclude that larger adequately powered trials are needed to confirm whether HMB-containing supplementation offers clinical benefit in this population.
Regional applicability
This Thai-conducted study is not based on United Kingdom populations or healthcare settings. Findings may have limited direct transferability to UK practice, as sarcopenia management and patient populations differ; however, the mechanistic question of HMB supplementation efficacy in cirrhosis-related muscle loss is internationally relevant and could inform future UK-based trials if larger studies confirm benefit.
Key measures
Appendicular skeletal muscle mass index (ASMI), fat-free mass index (FFMI), phase angle, handgrip strength, mid-arm muscle circumference (MAMC), 5-time chair stand test time
Outcomes reported
The study measured changes in muscle mass (ASMI, FFMI), muscle strength (handgrip), muscle quality (phase angle, mid-arm muscle circumference), and physical performance (5-time chair stand test) in patients with stable decompensated cirrhosis receiving HMB-containing oral nutritional supplement versus maltodextrin control for 12 weeks.
Topic tags
Dig deeper with Pulse AI.
Ask about this record, its theme or its relevance to UK farming and policy. Pulse AI uses selected catalogue evidence and cites the sources it draws on.